M Gaeta

Malignant gliomas and metastatic tumors are the most common forms of brain tumors. From a clinical perspective, neuroimaging plays a significant role, in diagnosis, treatment planning, and follow-up. To date MRI is considered the current clinical gold standard for imaging, however, despite providing superior structural detail it features poor specificity in identifying viable tumors in brain treated with surgery, radiation, or chemotherapy. In the last years functional neuroimaging has become largely widespread thanks to the use of molecular tracers employed in cellular metabolism which has significantly improved the management of patients with brain tumors, especially in the post-treatment phase. Despite the considerable progress of molecular imaging in oncology its use in the diagnosis of brain tumors is still limited by a few wellknown technical problems. Because 18F-FDG, the most common radiotracer used in oncology, is avidly accumulated by normal cortex, the low tumor/background signal ratio makes it difficult to distinguish the tumor from normal surrounding tissues. By contrast, radiotracers with higher specificity for the tumor are labeled with a short half-life isotopes which restricts their use to those centers equipped with a cyclotron and radiopharmacy facility. 11C-choline has been reported as a suitable tracer for neuroimaging application. The recent availability of choline labeled with a long half-life radioisotope as 18F increases the possibility of studying this tracer's potential role in the staging of brain tumors. The present review focuses on the possible clinical applications of PET/CT with choline tracers in malignant brain tumors and brain metastases, with a special focus on malignant gliomas.

In recent years, the SPECT/CT hybrid modality has led to a rapid development of imaging techniques in nuclear medicine, opening new perspectives for imaging staff and patients as well. However, while, the clinical role of positron emission tomography-computed tomography (PET-CT) is well consolidated, the diffusion and the consequent value of single-photon emission tomography-computed tomography (SPECT-CT) has yet to be weighed, Hence, there is a need for a careful analysis, comparing the "potential" benefits of the hybrid modality with the "established" ones of the standalone machine. The aim of this article is to analyze the impact of this hybrid tool on the diagnosis of diseases of the central nervous system, comparing strengths and weaknesses of both modalities through the use of SWOT analysis.

The facial lymph nodes are classified in five groups: mandibular, buccinator, infraorbital, malar and retrozygomatic nodes. This paper reports the CT appearance of neoplastic involvement of these nodes, an unusual and not well documented event. The CT examinations of 62 patients with a history of primary or recurrent cancer of the epidermal structures of the face, oral cavity and sinonasal region were retrospectively reviewed to assess the presence of facial adenopathy. Nine cases of neoplastic involvement of facial nodes were found. Most commonly the buccinator nodes (4 cases) were involved, the infraorbital, mandibular (2 cases) and retrozygomatic nodes (1 case) being less commonly involved. No malar nodes were found. Neoplastic involvement of these nodes was caused by squamous cell carcinoma in 6 cases, by adenocarcinoma in 2 cases and by a lymphoma in 1 case. Normal nodes could not be confidently identified on CT studies. CT diagnosis of neoplastic involvement of facial nodes is based on the presence of a nodular lesion which lies along the lymphatic pathways of the primary neoplasm in an anatomically compatible location. CT diagnosis of facial nodes is very important for treatment planning if the nodes are deep or at a distance from primary cancer. This is especially true for retrozygomatic and buccinator nodes.

The angiogram sign in chest CT is the demonstration of normally enhanced pulmonary branches within hypoattenuating lung parenchyma consolidation. In a retrospective review of the chest CT exams performed in a 2-year period, we identified the angiogram sign in 10 patients with lung consolidation; the diagnosis was central lung tumor with obstructive pneumonia in 4 patients, bronchioloalveolar carcinoma in 2 patients, postirradiation fibrosis in 1 patient, tuberculous pneumonia in 1 patient, lung lymphoma in 1 patient and metastasis from pancreatic tumor in 1 patient. The diagnosis was made with cytology and/or surgical specimen in 9 patients and with clinical-radiologic follow-up in 1 patient. The density, air and mucous bronchogram and the volume loss in the consolidated lung were also considered. The consolidated lung density was < 30 HU in 5 patients-one bronchioloalveolar carcinoma, one metastasis from pancreatic carcinoma and 3 obstructive pneumonia cases-, while it was > 30 HU in the extant 5 patients. The air bronchogram sign was observed in 4 cases-one bronchioloalveolar carcinoma, one metastasis, one postirradiation fibrosis and one lung lymphoma-, while a mucous bronchogram was observed in 3 patients with obstructive pneumonia. Lung volume was reduced only in 2 patients-one obstructive pneumonia and one postirradiation fibrosis. In our opinion, the CT angiogram sign must be considered a poorly specific sign, because it can be found in many pathologic processes, both benign and malignant. If associated with the other features of lung consolidation, the CT angiogram sign can help diagnose, together with clinical findings and the patient's history, the pathologic condition. Particularly, the angiogram sign within a hypoattenuated lung consolidation area can be found in obstructive pneumonia, while the angiogram sign within a hypoattenuated consolidation with an air bronchogram probably indicates a mucinous carcinoma with lipidic growth.